Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

119.23 -8.55 (-6.69%)
Streaming Delayed Price Updated: 9:57 AM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
69 70 Next >
Buy Bristol-Myers Squibb, Merck, 10-Year Treasury ETF And This Payments Stock: CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners chose Bristol-Myers Squibb Co. (NYSE: BMY) as his final trade. 
Via Benzinga
Stocks Sharply Lower As Political Gridlock Sets In
Stocks sold off today, falling victim to the likelihood of a political gridlock in Washington D.C. 
Via Talk Markets
Is Merck Too Dependent on Keytruda?
The company's top-selling drug brought in the most revenue last quarter and was also its fastest-growing product. 
Via The Motley Fool
7 No-Brainer Retirement Stocks to Buy for 2023 and Beyond
These no-brainer retirement stocks have proven to be amazingly consistent in delivering incredible returns for investors over time. 
Via InvestorPlace
Election Day Is Here: Which Politicians Are Profiting (Or Losing) On Stocks?
U.S. voters will spend the majority of Tuesday casting their ballots for the candidates they want to represent them in Congress, which consists of the House of Representatives and the Senate. 
Via Benzinga
Will Merck Continue Its Bullish Streak? A Wyckoff Analysis
According to the Wyckoff trading method, Merck's price structure is bullish with enough causes built over the years and lack of threatening supply. 
Via Talk Markets
What 7 Analyst Ratings Have To Say About Merck & Co
Merck & Co (NYSE:MRK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
These 3 Dividend ETFs Are a Retiree's Best Friend
This trio of exchange-traded funds has trounced the S&P 500 this year. 
Via The Motley Fool
Control Of Congress Up For Grabs In Midterms: 12 Stocks To Watch
As voters endeavor to select the congressional candidates they believe would best assist the U.S. in navigating through historical issues it is currently facing, investors are wondering what's going to... 
Via Benzinga
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga
Got $3,000? Here Are 3 Stocks to Buy and Hold for the Long Term
Great companies grow their top and bottom lines, but they also plug into trends rooted in cultural change, consumer convenience, and practicality. 
Via The Motley Fool
Merck & Co. (MRK) Q3 2022 Earnings Call Transcript
MRK earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Merck Q3 Earnings And Revenues Surpass Estimates
Merck came out with quarterly earnings of $1.85 per share. 
Via Talk Markets
Merck Outmaneuvers Exchange-Rate Headwinds For A Bullish Beat-And-Raise
The company's core business continues to perform well, though one-time items had an impact in the quarter. 
Via Investor's Business Daily
Dogs Of The Dow: An Outperforming Strategy In 2022
Via Talk Markets
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
Why Moderna Stock Soared Last Week
The biotech's promising drug pipeline could drive further gains for shareholders. 
Via The Motley Fool
Dogs Of The Dow: A Leading Strategy In 2022
At that time the Dow Dogs strategy had a positive year-to-date return versus the negative return of the Dow Jones Industrial Average Index and the S&P 500 Index. 
Via Talk Markets
Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review
The Dow and S&P 500 moved above a key level while the Nasdaq rose. 
Via Investor's Business Daily
Merck Clocks More Than 50% Drop In COVID-19 Treatment Sales, Revises Annual Guidance
Via Benzinga
Merck, Impinj, Clearway Energy And This Defense Play Are CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Clearway Energy Inc. (NYSE: CWEN) is a producer of renewable energy and tr 
Via Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation. 
Via InvestorPlace
Elon Musk & Philippine Billionaire Come Together For Satellite Internet Service In Southeast Asia, Disney May Track Your Theme Park Preferences, Struggling Credit Suisse Reveals Business Overhaul: Top Stories Thursday, Oct. 27
Benzinga 
Via Benzinga
Can Big Data Make Patient Care More Personalized And Effective?
It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets... 
Via Benzinga
US Stocks On Track For Mixed Start As Nasdaq Futures Sag Yet Again Amid Big Tech Woes; Traders Look Ahead To Q3 GDP Data, Apple, Amazon Earnings
Trading in the U.S. index futures points to a mixed opening by Wall Street stocks on Thursday, as tech earnings continue to disappoint. 
Via Benzinga
Dissecting The Dow Jones Industrial Average: Half Empty Or Half Full?
The Dow Jones Industrial Average is a leading index comprised of 30 stocks. Consequently, it has long been considered a great proxy for the stock market at large. 
Via Talk Markets
Earnings Outlook For Merck & Co
Merck & Co (NYSE:MRK) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will... 
Via Benzinga
Is Merck Moving Toward Another Blockbuster Drug Launch?
Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event. 
Via The Motley Fool
What Are Whales Doing With Merck & Co
A whale with a lot of money to spend has taken a noticeably bullish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 21 strange trades. 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.